'Gineksin', an 'Eunhaengip' Blood Circulation and Cognitive Impairment Remedy, Celebrates 30th Anniversary of Release

Jeon Gwang-hyun, President of SK Chemicals (center), and other executives and employees are cutting a commemorative cake at the 30th anniversary event of the release of Gineksin.

[Asia Economy Reporter Chunhee Lee] SK Chemicals' ginkgo leaf extract blood circulation and cognitive impairment improvement drug 'Gineksin-F' has celebrated its 30th anniversary since its launch.

SK Chemicals announced on the 6th that it held a 30th anniversary event for Gineksin at its Eco Lab headquarters in Pangyo, Seongnam, Gyeonggi Province. The event was attended by SK Chemicals President Kwanghyun Jeon, Pharma Planning Director Junghoon Kim, and Management Support Director Minhui Koo, who highlighted the achievements of Gineksin.

Since its release in 1992, Gineksin has sold over 2 billion tablets over 30 years, recording cumulative sales of 483.3 billion KRW as of last year, making it a steady seller for SK Chemicals. According to the pharmaceutical market research firm Ubist, Gineksin has maintained an unshakable first place with a 38% domestic market share in the ginkgo leaf blood circulation improvement segment last year.

Gineksin has efficacy in improving peripheral arterial blood circulation in the body through the 'three major blood circulation actions': reducing blood viscosity, vasodilation, and improving blood flow. When taken in high doses, in addition to improving blood circulation, it has been proven to improve memory decline and concentration, leading to the launch of the 240mg high-dose Gineksin in March last year.

It has also set various records. In December 1991, before its domestic release, it was the first domestic blood circulation improvement drug to be exported to three countries: Germany, the United States, and Argentina. Furthermore, from its first year of release in 1992, it caused a sensation by becoming the first domestic pharmaceutical product to surpass 10 billion KRW in domestic sales.

At the 30th anniversary event, SK Chemicals President Kwanghyun Jeon said, "Gineksin, which has maintained its position as the nation's ginkgo leaf medicine based on excellent product quality, has already reached its 30th anniversary," adding, "We will continue to strive to contribute to public health by improving blood circulation and cognitive function disorders."

This content was produced with the assistance of AI translation services.